Santen Pharmaceutical

Santen Pharmaceutical Co., Ltd.
Native name
 参天製薬株式会社
Public KK
Traded as TYO: 4536
OSE: 4536
Industry Pharmaceutical
Founded Osaka, Japan (1890 (1890))
Founder Kenkichi Taguchi
Headquarters Grand Front Osaka Tower A, 4-20 Ofuka-cho, Kita-ku, Osaka 530-8552, Japan
Key people
 Akira Kurokawa, (CEO and President)
Products
Revenue

$ 1.265 billion (FY 2012)

(¥ 119.066 billion) (FY 2012)

$ 175.661 million (FY 2012)

(¥ 16.521 billion) (FY 2012)
Number of employees
 3,050 (consolidated) (as of March 31, 2013)
Website Official website
Footnotes / references
[1][2]

Santen Pharmaceutical Co., Ltd. (参天製薬株式会社, Santen Seiyaku Kabushiki-gaisha), is Japanese pharmaceutical company, specializing in ophthalmology and rheumatology medicines. With its ophthalmic products Santen holds the top share within the Japanese market and is one of the leading ophthalmic companies worldwide, with its products being sold in over 50 countries.[3]

The company was founded in 1890 by Kenkichi Taguchi, as Taguchi Santendo, and in 1925, Santendo Co., Ltd. was established.[4] In 2014 Santen announced that it has entered into an agreement with Merck & Co. to purchase Merck's ophthalmology products.[5]

Business locations

Santen has 3 plants located in Hōdatsushimizu, Ishikawa, in Tampere and in Suzhou, 21 subsidiary companies located in Japan, the US, the Netherlands, Finland, United Kingdom & Ireland, Spain, Switzerland, Italy, France,[6] Germany, Sweden, China, South Korea, Taiwan, India, Thailand, Malaysia, the Philippines and Singapore. Its R&D center is located in Ikoma, Nara.[7][8]

References

  1. ↑ "Company Overview". Santen Pharmaceutical. Retrieved April 14, 2014.
  2. ↑ "Financial Highlights". Santen Pharmaceutical. Retrieved April 14, 2014.
  3. ↑ "Santen Announces Approval of DIQUASTM for Dry Eye Treatment in Japan". Business Wire. April 16, 2010. Retrieved April 14, 2014.
  4. ↑ "Company History". Santen Pharmaceutical. Retrieved April 14, 2014.
  5. ↑ McCarthy, Colleen (July 1, 2014). "Santen purchases ophthalmic assets from Merck". Optometry Times. UBM plc. Retrieved March 1, 2016.
  6. ↑ "Japan's Santen plans to buy Novagali for Eur 100 mln". Reuters. September 28, 2011. Retrieved April 14, 2014.
  7. ↑ "Global Operations". Santen Pharmaceutical. Retrieved April 14, 2014.
  8. ↑ "Santen Pharmaceutical Co., Ltd., Nara Research and Development Center" (in Japanese). Kansai Science City. Retrieved April 14, 2014.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.